[go: up one dir, main page]

ECSP003775A - INTEGRIN ALFA V RECEIVER ANTAGONISTS - Google Patents

INTEGRIN ALFA V RECEIVER ANTAGONISTS

Info

Publication number
ECSP003775A
ECSP003775A ECSP003775A ECSP003775A EC SP003775 A ECSP003775 A EC SP003775A EC SP003775 A ECSP003775 A EC SP003775A EC SP003775 A ECSP003775 A EC SP003775A
Authority
EC
Ecuador
Prior art keywords
alphav
antagonists
present
integrin
inhibiting
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Paul J Coleman
George D Hartman
Robert S Meissner
Mark E Duggan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to ECSP003775 priority Critical patent/ECSP003775A/en
Publication of ECSP003775A publication Critical patent/ECSP003775A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a derivados novedosos de ácido nonanoico, su síntesis, y su uso como antagonistas del receptor de integrina alfaV. Más particularmente, los compuestos de la presente invención son antagonistas de los receptores integrina alfaV beta3 y alfaV beta5 y son útiles para inhibir la resorción ósea, tratar y prevenir osteoporosis, e inhibir restenosis vascular, retinopatía diabética, degeneración macular, angiogenesis, ateroesclerosis, inflamación, artritis inflamatoria, enfermedad viral, cáncer y crecimiento de tumor metastásico.The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as alphaV integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the alphaV beta3 and alphaV beta5 integrin receptors and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation , inflammatory arthritis, viral disease, cancer and metastatic tumor growth.

ECSP003775 2000-11-17 2000-11-17 INTEGRIN ALFA V RECEIVER ANTAGONISTS ECSP003775A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP003775 ECSP003775A (en) 2000-11-17 2000-11-17 INTEGRIN ALFA V RECEIVER ANTAGONISTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP003775 ECSP003775A (en) 2000-11-17 2000-11-17 INTEGRIN ALFA V RECEIVER ANTAGONISTS

Publications (1)

Publication Number Publication Date
ECSP003775A true ECSP003775A (en) 2001-08-27

Family

ID=42041343

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP003775 ECSP003775A (en) 2000-11-17 2000-11-17 INTEGRIN ALFA V RECEIVER ANTAGONISTS

Country Status (1)

Country Link
EC (1) ECSP003775A (en)

Similar Documents

Publication Publication Date Title
DK1187592T3 (en) Alpha v integrin receptor antagonists
DK1040111T3 (en) Integrin receptor antagonists
DE69829996D1 (en) Integrin receptor Antagonist
ATE236626T1 (en) INTEGRIN ANTAGONIST
DE69830806D1 (en) INTEGRIN RECEPTOR ANTAGONISTS
DE60126496D1 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
ECSP003775A (en) INTEGRIN ALFA V RECEIVER ANTAGONISTS
ATE320258T1 (en) DIBENZOXAZEPINE ALPHA V INTEGRIN RECEPTOR ANTAGONIST
ECSP992897A (en) INTEGRIN RECEPTOR ANTAGONISTS
YU38200A (en) Integrin receptor antagonists
YU38300A (en) Integrin receptor antagonists